ArticleBMC cancer2025
Treatment patterns and survival outcomes of peripheral T-Cell lymphoma in Saudi Arabia: a 12-Year retrospective analysis.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Real-world outcomes of T cell lymphoma in a tertiary cancer center in Saudi Arabia.Annals of Saudi medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite the increased lymphoma burden in the Kingdom of Saudi Arabia (KSA) and poor prognostic factors in patients from KSA, limited data exist regarding the characteristics and outcomes of peripheral T-cell lymphoma (PTCL) patients. The present retrospective analysis evaluated the characteristics, treatment patterns, and survival outcomes of patients with PTCL in KSA.
methodsThe present retrospective chart review retrieved the data of patients with PTCL (aged ≥ 14 years) from two KSA centers. Data on clinical characteristics, treatment modalities, tumor response, and survival outcomes were obtained.
resultsNinety-nine patients were enrolled, with a mean age of 50.68 ± 1.62. The two most prevalent histological subtypes were peripheral PTCL-not otherwise specified (NOS; 38.4%) and ALK-negative anaplastic large cell lymphoma (ALK-ALCL; 26.3%). The majority of individuals (60.6%) were diagnosed with Ann Arbor Stage IV disease. Approximately 54% of individuals had an IPI ≥ 3 at the time of diagnosis. Combination chemotherapy was used as the first-line treatment in 32.3% of cases. Only 14.1% and 13.1% of the patients underwent ASCT and radiation therapy as first-line treatments, respectively. The five-year progression-free survival (PFS) and overall survival (OS) rates were 23.6% and 44%, respectively. A significant difference was observed in the 5-year PFS (p = 0.048) and OS rates (p = 0.017) between treatment regimens. Older age (Hazard ratio [HR] = 1.03, 95% confidence interval 1.00-1.05, p = 0.01) was an independent predictor of PFS. Likewise, B-symptoms and extranodal involvement were independent predictors of OS.
conclusionPatients with PTCL in KSA tend to present at a younger age and at more advanced disease stages compared to patients from Western and other Asian countries. The survival of patients with PTCL remains poor in the Kingdom, highlighting the need for standardized protocols for early diagnosis, prompt referral, and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.